Results 91 to 100 of about 52,382 (294)

Pyoderma Gangrenosum: A Retrospective Cohort Study of Comorbidities and Therapies in Over 65,000 Patients in the TriNetX Database

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis associated with systemic inflammatory diseases and malignancy. Although biologic therapies demonstrate efficacy in PG, the extent of their real‐world use remains incompletely characterized.
Rhiannon Grange, Tara Sholji, Marra Aghajani, Cindy Kok, John Frew   +4 more
wiley   +1 more source

Myelodysplastic syndromes: Classification

Journal of Applied Hematology, 2014
The updated WHO classification system for myelodysplastic syndromes (MDS) includes some new entities, in particular "refractory cytopenias with unilineage dysplasia (RCUD)". The following review article presents a short overview regarding all subvariants
Hans Peter Horny
doaj   +1 more source

Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells [PDF]

, 2012
DNA methylation might be the earliest somatic genome changes in prostate cancer that also play an important role in the process of tumor invasion, growth and metastasis.
D'Alessandro, Anna Maria, Di Clemente, Luigi, Di Pasquale, Boris, Dolo, Vincenza, Festuccia, Claudio, Gravina, Giovanni Luca, Mancini, Andrea, Marampon, Francesco, Muzi, Paola, Ranieri, Guido   +9 more
core   +1 more source

Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

The Laryngoscope, EarlyView.
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K. Evans, Hong‐Ho Yang, Christopher Dann, Dipti Sajed, Maie A. St. John   +7 more
wiley   +1 more source

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

Haematologica
Erythropoiesis-stimulating agents (ESAs) achieve hematological improvement-erythroid (HIE) in only 30% of ESA-naïve lower risk myelodysplastic syndrome (LR-MDS) patients with anemia, highlighting the need for developing novel drugs or new treatment ...
Chen Mei, Gaixiang Xu, Cuiping Zheng, Yaping Xie, Minming Li, Yanping Shao, Rongxin Yao, Shi Tao, Wei Jiang, Jun Guo, Zhiyin Zheng, Wei Wang, Xinping Zhou, Liya Ma, Li Ye, Yingwan Luo, Chunmei Yang, Wenjuan Yu, Wanzhuo Xie, Jie Jin, Hongyan Tong   +20 more
doaj   +1 more source

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes

Haematologica, 2011
Gene mutations and epigenetic changes have been shown to play significant roles in the pathogenesis of myelodysplastic syndromes. Recently, mutations in DNMT3A were identified in 22.1% of patients with acute myeloid leukemia.
Felicitas Thol, Claudia Winschel, Andrea Lüdeking, Haiyang Yun, Inna Friesen, Frederik Damm, Katharina Wagner, Jürgen Krauter, Michael Heuser, Arnold Ganser   +9 more
doaj   +1 more source

Different loss of material in recurrent chromosome 20 interstitial deletions in Shwachman-Diamond syndrome and in myeloid neoplasms [PDF]

, 2013
BACKGROUND: An interstitial deletion of the long arms of chromosome 20, del(20)(q), is frequent in the bone marrow (BM) of patients with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms (MPN), and it is ...
Lo Curto F, Mare L, Marletta C, Maserati E, Montalbano G, Pasquali F, Pressato B, Valli R   +7 more
core   +1 more source

Genetic analysis of primary lung interdigitating dendritic cell sarcomas

The Journal of Pathology, EarlyView.
Abstract Interdigitating dendritic cell sarcomas (IDCSs) are rare tumors that commonly arise in the hematopoietic system and rarely outside. The genetic drivers of IDCS carcinogenesis are unknown; therefore, therapeutic options are limited. We investigated somatic gene mutations and copy‐number alterations (CNAs) in nine IDCSs arising in the lung by ...
Mikhail S Ermakov, Juliana Faria Filipe, Sylvia Eidenhammer, German Ott, Iris Halbwedl, Karl Kashofer, Helmut Popper   +6 more
wiley   +1 more source

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

Haematologica, 2012
Background Reductions in transfusion requirements/improvements in hematologic parameters have been associated with iron chelation therapy in transfusion-dependent patients, including those with myelodysplastic syndromes; data on these reductions ...
Norbert Gattermann, Carlo Finelli, Matteo Della Porta, Pierre Fenaux, Michael Stadler, Agnes Guerci-Bresler, Mathias Schmid, Kerry Taylor, Dominique Vassilieff, Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rose   +12 more
doaj   +1 more source

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene [PDF]

, 2015
The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with
Al, M.J. (Maiwenn), Armstrong, N. (Nigel), Blommestein, H.M. (Hedwig), Deshpande, S. (Sohan), Kleijnen, J.M.P. (Jos), Noake, C. (Caro), Riemsma, R. (Rob), Ryder, S. (Steve), Severens, J.L. (Hans), Worthy, G. (Gill)   +9 more
core   +5 more sources